1) The document discusses materiovigilance, which refers to the close monitoring of medical devices post-marketing to identify adverse events and improve patient safety.
2) It outlines India's Materiovigilance Programme of India (MvPI), which aims to establish a nationwide system for reporting and analyzing medical device adverse events.
3) Under MvPI, 101 Medical Device Monitoring Centers have been set up across India to collect, analyze and report adverse events to the National Coordination Center at IPC in Ghaziabad.
The document provides an introduction to materiovigilance and adverse event following immunization (AEFI) surveillance programs in India. It discusses the need for monitoring medical devices and vaccines for safety. It outlines the objectives and organizational structure of India's Materiovigilance Program of India and AEFI surveillance program. Key activities include reporting and investigating adverse events, analyzing data, and taking corrective actions. The roles of various stakeholders like monitoring centers, regulatory authorities, and hospitals are also summarized.
The document discusses pharmacovigilance and adverse drug reaction (ADR) reporting in India. It provides information on the national pharmacovigilance program, including who can report ADRs, how to report them, and the benefits of reporting. It describes the ADR reporting process and forms for healthcare professionals and consumers. It also discusses other vigilance programs in India related to medical devices, vaccines, blood products, and several research projects conducted with these programs.
Materiovigilance programme of india by akhilesh sachanAkhilesh Sachan
The Materiovigilance Programme of India (MvPI) was launched in 2015 to study incidents related to medical devices and ensure patient safety. It allows dangerous devices to be removed from the market and defects to be addressed. The MvPI collects reports of device malfunctions, defects, or other issues directly from healthcare professionals and the public. It is coordinated by the Indian Pharmacopoeia Commission and Sree Chitra Tirunal Institute of Medical Sciences and Technology, with support from the National Health Systems Resource Centre. The program has established guidelines, forms, and monitoring centers to facilitate medical device safety surveillance in India.
This presentation is a brief overview of ICH-GCP guidelines. Although ICH-GCP is a very vast topic, still this presentation will cover almost all the points. The reader will be able to discuss about the roles and responsibilities of various personnel in clinical trials.
Adverse drug reaction monitoring and reportingTHUSHARA MOHAN
This document discusses types of adverse drug reactions and factors influencing them. It describes types A-E reactions, which include augmented, bizarre, chemical, delayed and end of treatment reactions. Polypharmacy, age, drug characteristics, gender, race and genetic factors can influence susceptibility. Detection methods include pre-marketing studies, post-marketing surveillance, underreporting and communicating reactions. Healthcare professionals should monitor high-risk patients and gather information to assess causality between drugs and adverse events. Underreporting is common due to various barriers but can be addressed through improved reporting systems and education.
If you are marketing your product in India you should comply these area of regulation.We give Services in getting manufacturing licences
ACCREDITED CONSULTANTS PVT.LTD
info@acplgroupindia.co.in
+919310040434
Pharmacovigilance Establishment in India and An overview on PvPImadhvi Chaubey
An overview on Pharmacovigilance Program establishment in India
Including National Pharmacovigilance Program . Objective of the program.
Pharmacovigilance program of India (PvPI)
Achievements of PvPI
The Haemovigilance Program of India
Future challenges of the program
1) The document discusses materiovigilance, which refers to the close monitoring of medical devices post-marketing to identify adverse events and improve patient safety.
2) It outlines India's Materiovigilance Programme of India (MvPI), which aims to establish a nationwide system for reporting and analyzing medical device adverse events.
3) Under MvPI, 101 Medical Device Monitoring Centers have been set up across India to collect, analyze and report adverse events to the National Coordination Center at IPC in Ghaziabad.
The document provides an introduction to materiovigilance and adverse event following immunization (AEFI) surveillance programs in India. It discusses the need for monitoring medical devices and vaccines for safety. It outlines the objectives and organizational structure of India's Materiovigilance Program of India and AEFI surveillance program. Key activities include reporting and investigating adverse events, analyzing data, and taking corrective actions. The roles of various stakeholders like monitoring centers, regulatory authorities, and hospitals are also summarized.
The document discusses pharmacovigilance and adverse drug reaction (ADR) reporting in India. It provides information on the national pharmacovigilance program, including who can report ADRs, how to report them, and the benefits of reporting. It describes the ADR reporting process and forms for healthcare professionals and consumers. It also discusses other vigilance programs in India related to medical devices, vaccines, blood products, and several research projects conducted with these programs.
Materiovigilance programme of india by akhilesh sachanAkhilesh Sachan
The Materiovigilance Programme of India (MvPI) was launched in 2015 to study incidents related to medical devices and ensure patient safety. It allows dangerous devices to be removed from the market and defects to be addressed. The MvPI collects reports of device malfunctions, defects, or other issues directly from healthcare professionals and the public. It is coordinated by the Indian Pharmacopoeia Commission and Sree Chitra Tirunal Institute of Medical Sciences and Technology, with support from the National Health Systems Resource Centre. The program has established guidelines, forms, and monitoring centers to facilitate medical device safety surveillance in India.
This presentation is a brief overview of ICH-GCP guidelines. Although ICH-GCP is a very vast topic, still this presentation will cover almost all the points. The reader will be able to discuss about the roles and responsibilities of various personnel in clinical trials.
Adverse drug reaction monitoring and reportingTHUSHARA MOHAN
This document discusses types of adverse drug reactions and factors influencing them. It describes types A-E reactions, which include augmented, bizarre, chemical, delayed and end of treatment reactions. Polypharmacy, age, drug characteristics, gender, race and genetic factors can influence susceptibility. Detection methods include pre-marketing studies, post-marketing surveillance, underreporting and communicating reactions. Healthcare professionals should monitor high-risk patients and gather information to assess causality between drugs and adverse events. Underreporting is common due to various barriers but can be addressed through improved reporting systems and education.
If you are marketing your product in India you should comply these area of regulation.We give Services in getting manufacturing licences
ACCREDITED CONSULTANTS PVT.LTD
info@acplgroupindia.co.in
+919310040434
Pharmacovigilance Establishment in India and An overview on PvPImadhvi Chaubey
An overview on Pharmacovigilance Program establishment in India
Including National Pharmacovigilance Program . Objective of the program.
Pharmacovigilance program of India (PvPI)
Achievements of PvPI
The Haemovigilance Program of India
Future challenges of the program
This document discusses pharmacovigilance, which involves monitoring the safety of drugs after they have been approved. It defines pharmacovigilance and explains why it is needed given limitations of clinical trials. It describes types of adverse drug reactions and how they are classified. It outlines the goals and processes of pharmacovigilance programs, including reporting adverse reactions, conducting causality assessments, and submitting periodic safety update reports. The overall aim is to ensure safe and effective use of medicines through continual monitoring and regulatory action.
The document discusses various methods used in pharmacovigilance including spontaneous reporting systems, case series, stimulated reporting, active surveillance methods like sentinel sites and drug event monitoring, use of registries, observational studies like cross-sectional, case-control and cohort studies, targeted clinical investigations and descriptive studies. It also outlines the key aims and shared responsibilities of pharmacovigilance among drug companies, regulatory authorities, doctors, pharmacists and nurses.
Spontenous adr reporting in india
PASSIVE survillence system, data assement
data aciqsition, data interpretation, what all information required in ADR form, WHEN TO REPORT
BLUE CARD,YELLOW CARD, WHO CODES
Pharmacovigilance is science of detection,
assessment, reporting and prevention of adverse
reactions to drug(s).
Major aims of pharmacovigilance are:
1. Early detection of hitherto unknown adverse
reactions and interactions
2. Detection of increases in frequency of (known)
adverse reactions
3. Identification of risk factors and possible
mechanisms underlying adverse reactions
4. Estimation of quantitative aspects of benefit/risk
analysis and dissemination of information needed to
improve drug prescribing and regulation.
complete description of causality assessment with the definition of basic terminologies.& relation with an adverse event and adverse drug reaction, causality terms & assessment criteria.
Pharmacovigilance involves monitoring approved drugs to detect adverse effects, assess risks, prevent harm and promote safe use. It aims to improve public health by identifying unknown risks from case reports and studies. Several methods are used including spontaneous reporting, active surveillance and observational studies. Organizations like WHO and regulatory authorities play important roles in pharmacovigilance. The goal is continual assessment of benefit-risk profiles to optimize treatment outcomes.
Pharmacovigilance and Materiovigilance, Drugs and Cosmetics Actshashi sinha
Due to side effects of Medicines and Medical Devices increasing day by day it is important to monitor the Adverse Events arising out of use of Medicines and Medical Devices. The Pharmacovigilance and Materiovigilance monitors adverse events arising our of usage of Drugs and Medical Devices respectively. This chapter also deals with Drugs and Cosmetics Act 1940 and their important provisions.
Pharmacovigilance is the science of monitoring the effects of medicines after they have been licensed for use, in order to identify new safety hazards and assess risks and benefits. It aims to improve patient care and safety in relation to medicine use. The thalidomide disaster in the 1960s demonstrated the need for formal pharmacovigilance systems to detect adverse drug reactions. Spontaneous reporting by healthcare professionals and mandatory reporting by manufacturers are key methods for collecting information on adverse drug events. Reports are assessed for causality and contribute to the ongoing evaluation of medicines to ensure their safe and effective use.
Designing of clinical study protocol rumana hameedRumana Hameed
This document provides guidance on designing clinical study documents, including protocols and case report forms (CRFs). It discusses key components of trial master files, protocols, and their amendments. Protocols should include background information, objectives, design, endpoints, inclusion/exclusion criteria, and plans for statistical analysis and publication. CRFs are important trial documents used to collect patient data uniformly. Their design should follow guidelines, with clear instructions and formatting. Errors in CRFs should be addressed through queries. Overall, the document outlines best practices for developing the main documents used to conduct clinical trials and collect trial data.
The document discusses the Yellow Card Scheme in the UK for reporting adverse drug reactions (ADRs). It defines an ADR and describes how common ADRs are, causing 6.5% of adult hospital admissions. It outlines how ADRs can be classified and factors that influence them. The Yellow Card Scheme acts as an early warning system to identify new ADRs and risks. Healthcare professionals, patients and the public can report suspected ADRs to the scheme to help continual drug safety monitoring.
This document discusses prescription auditing at a medical college and hospital. It defines prescription auditing and its objectives which include assessing irrational prescribing, detecting errors, and improving the quality of prescriptions. It outlines the audit process including forming a committee, setting criteria, collecting a sample of prescriptions, analyzing the data, generating a report, and creating an action plan. Key aspects of prescriptions that should be audited are completeness, legibility, rationality of medications prescribed, and adherence to treatment guidelines. The audit aims to promote rational drug use and reduce errors and costs to improve patient care.
breif notes on what is pharmacoepidemiology, why do we need pharmacoepidemiology, whats is its aim and its main applications, advantages and disadvantages
1) All health care professionals and pharmaceutical companies can report any suspected adverse drug reactions (ADRs), regardless of severity, to the nearest ADR monitoring center.
2) The ADR reporting process involves reporting to peripheral centers, then regional, zonal, and finally the national coordinating center (NPC) and Central Drugs Standard Control Organization (CDSCO). International reporting also occurs to the WHO Uppsala Monitoring Centre (WHO-UMC).
3) Complete information is required for ADR reporting, including patient information, a description of the adverse reaction, details on the suspected drug, management of the reaction, and reporter information.
This document provides an overview of pharmacovigilance. It defines key terms like drug, adverse event, and pharmacovigilance. It describes the drug development process including preclinical and clinical trials. It explains the need for pharmacovigilance during clinical trials and after marketing to monitor for adverse events. It discusses how pharmacovigilance benefits public health and drug manufacturers by improving drug safety.
various measures for the measurement of outcome such as incidence prevalence and other drug us measures are briefly discussed here with suitable examples and equations
Roles and Responsibilities in Clinical Trials of Investigator, Study Coordinator, Sponsor, Monitor, a Contract research organization.
The clinical trial, definition, description, Different types of clinical trials, phases of clinical trial.
The clinical trial study team.
Requirements of the clinical trial study team.
Clinical research team role.
GCP- Good clinical practices.
The spontaneous reporting system is a passive surveillance system where health professionals voluntarily report adverse drug reactions directly to regulatory authorities or pharmaceutical companies. It involves 3 main processes: 1) data acquisition from reported cases, 2) data assessment of individual cases and pooled data, and 3) data interpretation to generate safety signals. Countries have different reporting forms, like the Yellow Card used in the UK since 1964. Factors like educational campaigns and inclusion of reporting options in prescription pads have helped increase reporting rates in the UK. India's Pharmacovigilance Programme similarly encourages voluntary reporting of all suspected adverse reactions via established adverse drug monitoring centers.
The document discusses pharmacovigilance, which is defined as monitoring the effects of medicines to detect adverse drug reactions. It describes how pharmacovigilance aims to improve patient safety by contributing to assessments of drug benefit, harm, effectiveness and risk. The World Health Organization (WHO) coordinates global pharmacovigilance efforts through its Uppsala Monitoring Centre. India's Pharmacovigilance Programme of India (PvPI) was launched in 2010 to monitor adverse drug reactions among the Indian population and ensure medicines are used safely and rationally in India. PvPI is coordinated by the National Coordinating Centre and collaborates with WHO and India's drug regulatory authority, CDSCO.
The document discusses India's Materiovigilance programme which monitors incidents involving medical devices. It was established to improve device quality and safety after incidents like incubator fires led to infant deaths. The programme coordinates various centers to collect, analyze and signal adverse event reports which help regulators take action. It aims to constantly enhance medical device oversight and protect patients.
Establish Pharmacovigilance Centres in hospital and National Programmes.pptxPiyushZala5
Three key points:
1) Pharmacovigilance centers play an important role in both hospitals and the pharmaceutical industry by monitoring adverse drug reactions and ensuring drug safety.
2) Establishing a pharmacovigilance center requires obtaining approvals, developing reporting forms, educating staff, creating a database to store reports, and networking with other organizations.
3) India has established a national pharmacovigilance program called PvPI coordinated by the Indian Pharmacopoeia Commission to monitor drug safety, expand reporting nationwide, and collaborate with other health programs.
This document discusses pharmacovigilance, which involves monitoring the safety of drugs after they have been approved. It defines pharmacovigilance and explains why it is needed given limitations of clinical trials. It describes types of adverse drug reactions and how they are classified. It outlines the goals and processes of pharmacovigilance programs, including reporting adverse reactions, conducting causality assessments, and submitting periodic safety update reports. The overall aim is to ensure safe and effective use of medicines through continual monitoring and regulatory action.
The document discusses various methods used in pharmacovigilance including spontaneous reporting systems, case series, stimulated reporting, active surveillance methods like sentinel sites and drug event monitoring, use of registries, observational studies like cross-sectional, case-control and cohort studies, targeted clinical investigations and descriptive studies. It also outlines the key aims and shared responsibilities of pharmacovigilance among drug companies, regulatory authorities, doctors, pharmacists and nurses.
Spontenous adr reporting in india
PASSIVE survillence system, data assement
data aciqsition, data interpretation, what all information required in ADR form, WHEN TO REPORT
BLUE CARD,YELLOW CARD, WHO CODES
Pharmacovigilance is science of detection,
assessment, reporting and prevention of adverse
reactions to drug(s).
Major aims of pharmacovigilance are:
1. Early detection of hitherto unknown adverse
reactions and interactions
2. Detection of increases in frequency of (known)
adverse reactions
3. Identification of risk factors and possible
mechanisms underlying adverse reactions
4. Estimation of quantitative aspects of benefit/risk
analysis and dissemination of information needed to
improve drug prescribing and regulation.
complete description of causality assessment with the definition of basic terminologies.& relation with an adverse event and adverse drug reaction, causality terms & assessment criteria.
Pharmacovigilance involves monitoring approved drugs to detect adverse effects, assess risks, prevent harm and promote safe use. It aims to improve public health by identifying unknown risks from case reports and studies. Several methods are used including spontaneous reporting, active surveillance and observational studies. Organizations like WHO and regulatory authorities play important roles in pharmacovigilance. The goal is continual assessment of benefit-risk profiles to optimize treatment outcomes.
Pharmacovigilance and Materiovigilance, Drugs and Cosmetics Actshashi sinha
Due to side effects of Medicines and Medical Devices increasing day by day it is important to monitor the Adverse Events arising out of use of Medicines and Medical Devices. The Pharmacovigilance and Materiovigilance monitors adverse events arising our of usage of Drugs and Medical Devices respectively. This chapter also deals with Drugs and Cosmetics Act 1940 and their important provisions.
Pharmacovigilance is the science of monitoring the effects of medicines after they have been licensed for use, in order to identify new safety hazards and assess risks and benefits. It aims to improve patient care and safety in relation to medicine use. The thalidomide disaster in the 1960s demonstrated the need for formal pharmacovigilance systems to detect adverse drug reactions. Spontaneous reporting by healthcare professionals and mandatory reporting by manufacturers are key methods for collecting information on adverse drug events. Reports are assessed for causality and contribute to the ongoing evaluation of medicines to ensure their safe and effective use.
Designing of clinical study protocol rumana hameedRumana Hameed
This document provides guidance on designing clinical study documents, including protocols and case report forms (CRFs). It discusses key components of trial master files, protocols, and their amendments. Protocols should include background information, objectives, design, endpoints, inclusion/exclusion criteria, and plans for statistical analysis and publication. CRFs are important trial documents used to collect patient data uniformly. Their design should follow guidelines, with clear instructions and formatting. Errors in CRFs should be addressed through queries. Overall, the document outlines best practices for developing the main documents used to conduct clinical trials and collect trial data.
The document discusses the Yellow Card Scheme in the UK for reporting adverse drug reactions (ADRs). It defines an ADR and describes how common ADRs are, causing 6.5% of adult hospital admissions. It outlines how ADRs can be classified and factors that influence them. The Yellow Card Scheme acts as an early warning system to identify new ADRs and risks. Healthcare professionals, patients and the public can report suspected ADRs to the scheme to help continual drug safety monitoring.
This document discusses prescription auditing at a medical college and hospital. It defines prescription auditing and its objectives which include assessing irrational prescribing, detecting errors, and improving the quality of prescriptions. It outlines the audit process including forming a committee, setting criteria, collecting a sample of prescriptions, analyzing the data, generating a report, and creating an action plan. Key aspects of prescriptions that should be audited are completeness, legibility, rationality of medications prescribed, and adherence to treatment guidelines. The audit aims to promote rational drug use and reduce errors and costs to improve patient care.
breif notes on what is pharmacoepidemiology, why do we need pharmacoepidemiology, whats is its aim and its main applications, advantages and disadvantages
1) All health care professionals and pharmaceutical companies can report any suspected adverse drug reactions (ADRs), regardless of severity, to the nearest ADR monitoring center.
2) The ADR reporting process involves reporting to peripheral centers, then regional, zonal, and finally the national coordinating center (NPC) and Central Drugs Standard Control Organization (CDSCO). International reporting also occurs to the WHO Uppsala Monitoring Centre (WHO-UMC).
3) Complete information is required for ADR reporting, including patient information, a description of the adverse reaction, details on the suspected drug, management of the reaction, and reporter information.
This document provides an overview of pharmacovigilance. It defines key terms like drug, adverse event, and pharmacovigilance. It describes the drug development process including preclinical and clinical trials. It explains the need for pharmacovigilance during clinical trials and after marketing to monitor for adverse events. It discusses how pharmacovigilance benefits public health and drug manufacturers by improving drug safety.
various measures for the measurement of outcome such as incidence prevalence and other drug us measures are briefly discussed here with suitable examples and equations
Roles and Responsibilities in Clinical Trials of Investigator, Study Coordinator, Sponsor, Monitor, a Contract research organization.
The clinical trial, definition, description, Different types of clinical trials, phases of clinical trial.
The clinical trial study team.
Requirements of the clinical trial study team.
Clinical research team role.
GCP- Good clinical practices.
The spontaneous reporting system is a passive surveillance system where health professionals voluntarily report adverse drug reactions directly to regulatory authorities or pharmaceutical companies. It involves 3 main processes: 1) data acquisition from reported cases, 2) data assessment of individual cases and pooled data, and 3) data interpretation to generate safety signals. Countries have different reporting forms, like the Yellow Card used in the UK since 1964. Factors like educational campaigns and inclusion of reporting options in prescription pads have helped increase reporting rates in the UK. India's Pharmacovigilance Programme similarly encourages voluntary reporting of all suspected adverse reactions via established adverse drug monitoring centers.
The document discusses pharmacovigilance, which is defined as monitoring the effects of medicines to detect adverse drug reactions. It describes how pharmacovigilance aims to improve patient safety by contributing to assessments of drug benefit, harm, effectiveness and risk. The World Health Organization (WHO) coordinates global pharmacovigilance efforts through its Uppsala Monitoring Centre. India's Pharmacovigilance Programme of India (PvPI) was launched in 2010 to monitor adverse drug reactions among the Indian population and ensure medicines are used safely and rationally in India. PvPI is coordinated by the National Coordinating Centre and collaborates with WHO and India's drug regulatory authority, CDSCO.
The document discusses India's Materiovigilance programme which monitors incidents involving medical devices. It was established to improve device quality and safety after incidents like incubator fires led to infant deaths. The programme coordinates various centers to collect, analyze and signal adverse event reports which help regulators take action. It aims to constantly enhance medical device oversight and protect patients.
Establish Pharmacovigilance Centres in hospital and National Programmes.pptxPiyushZala5
Three key points:
1) Pharmacovigilance centers play an important role in both hospitals and the pharmaceutical industry by monitoring adverse drug reactions and ensuring drug safety.
2) Establishing a pharmacovigilance center requires obtaining approvals, developing reporting forms, educating staff, creating a database to store reports, and networking with other organizations.
3) India has established a national pharmacovigilance program called PvPI coordinated by the Indian Pharmacopoeia Commission to monitor drug safety, expand reporting nationwide, and collaborate with other health programs.
REGULATION AND STANDARDS OF MEDICAL DEVICES IN UGANDABrian Matovu
This slides briefly describe the role of different government bodies in regulation and setting of standards in Uganda. This work was presented on 17th November 2016 at the 5th East African Regional Scientific Conference and Exhibition in Nairobi Kenya at Meridian Hotel. ENJOY!!
National programmes related to Pharmacovigilance Nitin Kale.pptxNitinKale46
Establishment of national pharmacovigilance systemsfor the reporting of adverse events, including nationaland, if appropriate, regional pharmacovigilance centres. Development of legislation/regulation for medicinemonitoring. National policy development (to include costing,budgeting and financing). The Pharmacovigilance Programme of India (PvPI) was operationalized in July 2010 by the Ministry of Health and Family Welfare, Government of India with the mission to safeguard the health of Indian population by ensuring that the benefits of use of medicine outweigh the risks associated with its use.
The document discusses India's national pharmacovigilance programs. It was launched in 2010 by the Central Drugs Standard Control Organisation to safeguard public health by monitoring adverse drug reactions. The program is coordinated by the National Coordinating Centre at AIIMS which oversees adverse event reporting from Adverse Drug Reaction Monitoring Centers across India and shares data with the WHO's Uppsala Monitoring Centre for the global database. The pharmacovigilance program aims to improve patient safety by monitoring drug safety and reducing risks from medication use.
National Patient Safety Implementation_Dr Ruchi Kushwaha.pptxDr Ruchi Kushwaha
This document outlines the National Patient Safety Implementation Framework (NPSIF) for India from 2018-2025. The key points are:
1. The NPSIF aims to improve patient safety across all levels of healthcare in India to progress toward universal health coverage. Its goals are to establish structural systems and a competent workforce to support patient safety.
2. Strategic objectives include improving safety systems at national and facility levels, establishing adverse event reporting, ensuring a trained workforce, preventing infections, implementing safety campaigns, and promoting research.
3. Action plans and principles focus on strengthening legislation, accreditation, communication, and patient-centered care to establish a culture of safety in Indian healthcare.
This document discusses pharmacovigilance in India, both past and present. It notes that India did not previously have a formal pharmacovigilance system, but initiated activities in 1986 and joined the WHO program in 1997. The National Pharmacovigilance Program was launched in 2004 and became operational in 2005. It has since expanded to include 90 monitoring centers across India. The program aims to ensure drug safety, identify new adverse drug reactions, and support regulatory decision making. Future prospects include expanding the program further and implementing hemovigilance and biovigilance initiatives to monitor blood and medical devices.
Pharmacovigilance Programme of India (PvPI)Jamshed Ahmad
Pharmacovigilance Programme of India (PvPI) was initiated in July 2010 to monitor adverse drug reactions in India. It is coordinated by the Central Drugs Standard Control Organization and has a National Coordination Centre located at the Indian Pharmacopoeia Commission. The objectives of PvPI are to create a nationwide patient safety reporting system, analyze benefit-risk ratios of medicines, and support regulatory decision making. MAMC has established an ADR Monitoring Centre as part of PvPI, which has reported over 135 cases and monitors reactions to drugs like ceftriaxone, dapsone, and phenytoin.
Management of calibration and testing laboratory of medical equipments in ind...Beluh Mabasa Ginting
There are available 2.048 hospitals and 9.731Primary Health Care facilities at district are at Indonesia. All the health care facilities have the medical electrical equipment and most of them must be testing and calibration by accraditated laboratories to make sure that all the ME comply to standard for patient safety.
This document provides an overview of pharmacovigilance in India, including:
- The history of pharmacovigilance efforts in India from 1986 to the present.
- The objectives and goals of the current Pharmacovigilance Program of India (PvPI), including establishing a nationwide safety reporting system and expanding electronic reporting.
- The roles and responsibilities of stakeholders like the National Coordinating Center, Advisory Monitoring Centers, and CDSCO in the PvPI.
NASSCOM CoE IoT spearheaded a high-level industry roundtable to discuss firsthand the challenges & opportunities in India’s clinical trial industry and how technology can accelerate development
1. The document discusses recommendations for improving oversight of health IT to better protect patient safety. It proposes a risk-based framework where the level of oversight is determined by factors like the type of IT and potential for patient harm.
2. Key components of the proposed framework include adherence to safety standards, supporting best practices development, and facilitating reporting of safety events to create a learning environment.
3. The framework aims to leverage existing processes, protect innovation, and involve developers, implementers and users while avoiding regulatory duplication between agencies like FDA, ONC and FCC.
IRJET- A System for Complete Healthcare Management: Ask-Us-Health A Secon...IRJET Journal
This document proposes a system called ASK-US-HEALTH that uses machine learning algorithms and data mining to provide healthcare management. It aims to help patients access a second medical opinion by entering symptoms and receiving the probable diagnosis. It would also provide doctor recommendations and store patient medical histories and prescriptions. The system intends to improve healthcare access and help manage patient care and data for research through connecting patients, doctors, and nearby pharmacies via a web application.
This document discusses adverse drug reaction reporting and pharmacovigilance in India. It provides background on the pharmaceutical industry in India and defines adverse drug reactions and events. It describes the origins of pharmacovigilance from past drug safety issues. It outlines the various adverse drug reaction reporting centers in India and discusses the importance of pharmacovigilance for public health. It also covers communication in pharmacovigilance, roles and responsibilities, and challenges to the system in India.
ESTABLISHMENT OF PHARMACOVIGILANCE (Clinical Research & Pharmacovigilance).pptxDureshahwar khan
The contents in these slides include Establishment of PV centres in hospital& Industry, National programmes related to PV, and Roles & responsibilities in PV.
Medical Devices , regulations and e health solutionsshashi sinha
Medical Devices are now regulated in India. It is essential to know about the Medical Devices Regulations and how it is being implemented. Must know for all the manufacturers, importers and Distributors of Medical Devices.
Safety monitoring and reporting of adverse events of medical devices national...Vivek Nayak
This document outlines safety monitoring and adverse event reporting for medical devices from national and international perspectives. It defines medical devices and their classification system. Approval processes in India are discussed, along with the Materiovigilance Program of India for post-marketing surveillance. Adverse events must be reported within defined timeframes. International regulatory bodies like the FDA and MHRA also have mandatory reporting requirements. The limitations of current monitoring and reporting are noted.
The document discusses a global initiative to collect and share clinical engineering success stories from around the world. Over 150 success stories were submitted from 90 countries, falling under categories like innovation, improved access, health systems, healthcare technology management, safety and quality, and e-technology. The stories demonstrate how health technology has improved key healthcare processes and outcomes in various regions. The collection of success stories will be presented to the World Health Organization to promote best practices in health technology management.
ABSTRACT- There are various diseases which are preventable and one of high priority amongst them is the blindness.
Owing to insufficient ophthalmological healthcare facilities in the peripheral setup, the concept of camp surgery came into
existence for the developing nations so that maximum cases could be treated at a single sitting within a nominal
expenditure. Unfortunately if something goes wrong during mass surgery many people have to pay the price for it in terms
of permanent loss of vision. Hence it is of utmost importance that when so many people are getting operated for a
particular operation, there should not be any compromise in quality of care and standards of delivery of health services.
Key words- Cataract, Blindness, NPCB, Sterilization
Minimum requirements for a functional pharmacovigilance systemPriti Gupta
The document outlines minimum requirements for a functional national pharmacovigilance system. It defines pharmacovigilance and describes the development of minimum requirements through consultation with experts. The minimum requirements include: having a national pharmacovigilance center with dedicated staff and funding; a national system for spontaneous reporting of adverse drug reactions using a standard form; a national database for managing reports; a national advisory committee to provide technical assistance on assessing and managing risks; and a communication strategy for routine updates and crisis response.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
2. Materiovigilance
Study and follow incidents that might
result from using medical devices.
It enables dangerous devices to be
withdrawn from the market and to
eliminate faults in medical devices
Intention of constantly improving the
quality of devices and providing patients
and users with increased safety.
3. Medical device is defined as any instrument,
equipment, material or other article used on its own or
jointly, including software required for it to function
correctly, which is intended by the manufacturer to be
used on humans for the following purposes :
for diagnostic, prevention, control, treating
or diminishing an illness
for diagnostic, control, treating, for diminishing or
compensating an injury or handicap,
for studying, replacing or modifying part of the
anatomy or a physiological process
for mastering conception and whose principal
intended action in or on the human body is not
obtained by pharmacological or immunological
means or by metabolism but whose function can be
assisted in such a way.
Materiovigilance
4. ➢Medical Devices come under Schedule R1.
➢At present, provisions related to import,
manufacture, distribution and sale of
medical devices are covered under the
Drugs and Cosmetics Act, 1940 and the
Drugs and Cosmetics Rules, 1945
Materiovigilance
5. ➢ After several horrific cases of malfunctioning
medical devices, like babies being burnt to death due
to short circuits in incubators or hip implants
causing blood poisoning etc.
➢ The Ministry of Health and family Welfare
(MoHFW) has approved a commencement of
“Materiovigilance Programme of India (MvPI)”
vide approval dated 10/02/2015 in an effort to
ensure safety of medical devices.
Materiovigilance
6. Need for MvPI ?
6
24 infants died in the
space of 72 hours in two
government hospitals of
Murshidabad in West
Bengal-Jul 17, 2011
Three-day-old killed after
incubators caught fire in a
hospital in Ahmedabad. -
December 2008
Five newborns
receiving treatment for
jaundice at a
government hospital in
northern India died as a
fire broke out in its
phototherapy unit. Nov
16, 2009
An 8-minute power
cut at a premier
hospital in
Punducherry ended
in the loss of three
lives -09/03/2017
11. Scope
To analyse the benefit-risk ratio of medical devices
To generate evidence based information on safety of
medical devices
To support CDSCO in the decision-making process
on use of medical devices
To communicate the safety information on use of
medical devices to various stakeholders to minimise
the risk.
To collaborate with other healthcare organisations for
the exchange of information and data management.
12. 1. PGIMER, Chandigarh
2. CMC Vellore
3. AIIMS, New Delhi
4. Dayanand Medical College and Hospital, Ludhiana
5. National Institute of Mental Health And Neurosciences
(NIMHANS), Karnataka
Medical Device Adverse Event
Monitoring Centers (MDMCs)
13. 6. Glocal Group of Hospitals, Kolkata
7. Narayna Hrudalaya Hospital, Bengaluru
8. Jawaharlal Institute of Postgraduate Medical
Education and Research (JIPMER), Puducherry
9. Sanjay Gandhi Post Graduate Institute of Medical
Science, Lucknow
10. Bankura Sammilani Medical College, West Bengal
Medical Device Adverse Event
Monitoring Centers (MDMCs)
14. Programme Communication
CDSCO-Headquarter,
New Delhi
National Coordination Centre
IPC, Ghaziabad
Technical
Support &
Resource
Centre
NHSRC,
New-Delhi
National
Collaborati
on Centre
SCTIMST,
Kerala
AMCs/MDMCs
Healthcare Professionals
CDSCO Zonal / Subzonal
Offices
Medical Device
Industries in India
Steering
Committee
Working
Group
Core
Technical
Committee
15. Roles and responsibilities
▶ Each MDMC under MvPI is assigned with a
coordinator and a Research Associate responsible
for its functioning .
▶ The coordinator is responsible for sending the
consolidated monthly reports of its MDMC to NCC.
▶ The Research Associate is responsible for collection
and follow-up of MDAEs. All MDAE reports have to
be sent to National Coordination Centre (NCC) for
review and analysis.
▶ Feedback to all healthcare professionals involved in
reporting is to be sent by the Coordinator.
Medical Device Adverse Event
Monitoring Centers (MDMCs)
17. Roles and responsibilities
▶ IPC functions as National Coordination Centre (NCC)
for MvPI.
▶ The main responsibility of NCC is to coordinate with
all partners of the programme.
▶ Organising various meetings like steering committee,
working group, core technical committee meetings etc.
▶ Recognition of new Medical Device Adverse Event
Monitoring Centres (MDMCs) of public and private
hospitals across the country.
Indian Pharmacopoeia Commission
(IPC)
18. Roles and responsibilities contd....
▶ Recruitment and deployment of manpower (All MvPI
staff shall be appointed & work under the
administrative control of NCC-PvPI).
▶ Data collection, collation, analysis and signal
detection and outcome to be communicated to
CDSCO for relevant regulatory actions.
▶ IPC is the sole Custodian for MvPI database.
▶ Publication and dissemination of standard operating
procedures, guidance documents, newsletters,
training manuals etc. with technical support from
NHSRC and SCTIMST.
19. ▶ Reporting all concerned issues to CDSCO
▶ Collaborating with International Authorities
▶ Issue of medical device alert for awareness and
knowledge
▶ Providing financial support to SCTIMST, NHSRC and
MDMCs.
▶ Providing financial support to organise MvPI awareness
program across the country
Roles and responsibilities contd....
21. Roles and Responsibilities
▶ SCTIMST, as the National Collaboration Centre,
shall support the programme in all technical
matters.
▶ Responsible to collaborate with NCC-PvPI for further
follow-up/ analysis in case of Serious Adverse Event
with MDMCs.
▶ Lend Technical support for organising programme,
continuous professional development education on
Materiovigilance as and when considered necessary
by NCC-MvPI.
Sree Chitra Tirunal Institute for Medical
Sciences and Technology (SCTIMST)
22. ▶ To provide research & development/ testing support
facilities to the programme.
▶ To provide technical support in data analysis and
release of medical device alerts.
Roles and responsibilities contd....
24. Roles and responsibilities
▶ The Healthcare Technology Division of NHSRC acts
as a technical support partner for MvPI.
▶ To provide technical support/guidance on
preparation/ review of standard operating procedures,
guidance documents, newsletters, training manuals
etc.
▶ Lend Support to NCC-PvPI in identification of new
MDMC.
▶ Lend Technical support on the activities of National
Collaboration Centre and National Coordination
Centre including training programme.
National Health System Resource
Centre (NHSRC)
25. ▶ Drafting documents for the MvPI related
activities.
▶ Explore possibility of integrating data
mining/ data analytics, to adverse event
reports.
▶ Provide technical advice on setting-up of
online adverse events data collection and
release of medical device alerts via
Email/SMS etc.
Roles and responsibilities contd....
26. ▶ Lend support for creating awareness
program among medical device
manufactures /healthcare organisation.
▶ NHSRC shall also coordinate with other
partners as per need.
Roles and responsibilities contd....
27.
28. Roles and responsibilities
▶ The CDSCO is the National Regulatory
Authority ensure safety, efficacy and quality
standards of pharmaceuticals, medical devices
and vaccines.
▶ Responsible for taking appropriate regulatory
decisions/related actions based on the
recommendation NCC- MvPI.
Central Drugs Standard Control
Organization (CDSCO)
29. ▶ Lend support to NCC-MvPI in sharing
International information Medical Device
Regulators Forum (MDRF), Asian
Harmonization Working Party (AHWP) and
other forums organised by regulatory bodies
of other countries.
▶ Shall convene meetings with the NCC- MvPI,
SCTIMST & NHSRC for monitoring, review
and further advice on medical devices safety.
Roles and responsibilities contd....
30. ▶ Auditing/ inspecting of MDMCs and National
Collaborating Centre from time to time
▶ Providing administrative support to run MvPI.
Roles and responsibilities contd....
31. ▶ Identification and recognition of Ten Medical
Device Adverse Event Monitoring Centres
(MDMCs) across the country.
▶ Constituted steering committee and working
group and conducted two meetings of both.
▶ Medical Device Adverse Event (MDAE) reporting
form developed
▶ Guidance document for Materiovigilance
Programme of India (version 1.0) prepared in
consultation with NHSRC and SCTIMST
The progress made till date
32. ▶ Recruitment of 05 Research Associates
completed & remaining 10 posts are under
process
▶ Interactive meeting held with Medical Device
manufacturers and Associations
▶ Various review meetings held with the MvPI
partners
▶ Till date, NCC has received more than 200
MDAE reports
The progress made till date
contd....
37. What to report ?
Dysfunction or any change of the
characteristics and/or performance of a
device
Inadequacy in the labeling or instructions
Not only serious incidents but also the
cases where there was a risk of a serious
incident but that incident was avoided due
to the attention and action of the relevant
people
Materiovigilance
40. EXAMPLES:
• A batch of out-of-specification blood glucose
test strips is released by manufacturer
• Patient uses strips according to instructions,
but readings provide incorrect values leading
to incorrect insulin dosage, resulting in
hypoglycaemic shock and hospitalization.
Materiovigilance